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Abstract: Serum levels of the initiating complement component CC1q) in the classical 
pathway and those of an essential triggering component CC3) in the altemative pathway 
were quantified immunochemically in parallel with those of the immunonoglobulin G (IgG) 
in BALB/c mice， each of which was given a single dose of cyclophosphamide CCY) and/or 
rabbit anti-mouse-thymocyte-globulin Canti-TG) intraperitoneally. In the CY -treated 
mice， both C1q and IgG levels were significantly suppressed from 2 through 14 days after 
the treatment; such suppression was more conspicuous in male than in female mice. In 
contrast， C3 levels were markedly increased in these mice of both sexes from 2 through 7 
days after the same treatment. In anti-TG-treated mice of both sexes， only C1q levels were 
significastly suppressed from 2 through 10 days after the treatment ; however， neither their 
C3 nor IgG levels were much influenced. Both T and B lymphocytes in peripheral blood of 
these mice were significantly diminished: CY affected more severely B cells ; in contrast， 
anti-TG had a more severe influence on T cels. These results suggest that there may be 
some metabolic and/or developmental interrelationships among serum C1q levels， functions 
of immune lymphocytes， and their producing immunoglobulins and/or lymphokines. 
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INTRODUCTION 
The complement system consists of a set of some 20 distinct proteins， forming a complex 
biological system which fulfils various functions. This system not only plays important roles 
in host defence mechanisms but also is implicated in disease processes involving cyotoxic and 
immune complex-mediated hypersensitivites. For modulating these diverse biological activ-
ities， the system must be activated in the classicaF) or in the alternative pathway2). C1q is the 
triggeming component of the classical pathway， and it is a subcomponent of the first component 
CCl); C1 is composed of three different subcomponents， namely C1q， C1r and C1s. This 
subcomponent can interact not only with some classes of immunoglobulin(IgG and IgM)in the 
form of antigen-antibody complexes but also with non-antibody-substances， e. g. polyanions， 
polycations， etc. C3 is the third component of complement actually reacts fourth， and plays the 
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central role of the classical pathway. In addition， the C3 participates in the alternative pathway 
as an essential triggering component together with factots B and D. C3 interacts mainly with 
non-antibody-substances such as yeasts or bacterial lipopolysaccharide. 
Serum C1q is mainly produced in columnar cells of the small intestine3) and/or in the 
monocyte-macrophage lineage4)， and its levels have been reported to correlate with serum IgG 
levels in patients with a variety of immunoglobulin anomalies5)，6)， as well as in normal mice 
among vamious strains7). Several reports have shown that various types of cells possess 
specific receptors for C1q (C1qR)8)，9l， and have suggested that this subcomponent plays a 
potential role in the regulation of B cel functions. In fact， recent in vitro studies have shown 
that C1q down-regulates the secretion of IL-1-1ike activity by B lymphoblastoid celllines10) and 
induces their anti-proliferative response1) probably through the interaction of the collagenous 
tail12) of C1q and C1qR. It has been also shown that C1q significantly augments immunoglobuin 
production by human B lymphocytes in the presence of the T lymphocytes， perphaps through 
C1qR13) and in the absence of T cells most likely at the level of glycolation or secretion of 
immunoglobulin molecules14). C3 is synthesized by liver parenchymal cells3)15)， and by the 
monocyte-macrophage lineage8)16)17). In the early 1970s a regulatory link between this C3 and 
the production of antibody was also postulated18)ー20) Other complement components have been 
shown to have immunoregulatory functions， including C3a， which suppresses， and C5a and its 
fragment， which enhances in vitro antibody formation21). In addition， C5a has been shows to 
stimulate IL-1 production by monocytes2). Thus immunoregulatory links of C1q， C3 and its 
fragment， and of C5a have been gradually well analyzed in vitro. However， in vivo studies on 
immunoregulatory mechanisms by complement components are stil largely limited. 
In this study， we have， therefore， artificially regulated B and T cel functions in mice by in 
vivo administration of CY and/or anti-TG， and measured immunochemically their serum levels 
of C1q and C3， which should reflect the sum of their biosynthesis and catabolism， in parallel 
with those of the serum IgG. It is reported that CY suppresses both T and B cel populations， 
but that anti TG 
MATERIALS AND METHODS 
Animals and their treatment with CY or anti-TG 
BALB/ c mice of both sexes (from 2 to 6 months old， 20-25 g body weight， total 212 mice) 
were used. The mice， originally a gift from the Center for Labora.tory Animals in the Research 
Institute for Microbial Diseases， Osaka University (Osaka， Japan)， have been maintained by 
sister-brother mating in our laboratory. Each of these mice was given a single intraperitoneal 
dose of CY (20 mg/ml in sterile water in doses of 300μg/ml or 400μg/ml body weight; Sigma 
Chemical Co St. Louis， MO， USA) or a sterile rabbit anti-TG (0.2 ml) (Wako Pure Chemical 
Industries， Ltd.， Osaka， J apan) as indicated in the instruction manual for this antiserum by the 
company. The in vivo potency of this anti-TG in abrogating T cel functions was established 
by the supplier in prolonging the survival of allograft skin. Each of the control mice was given 
a single intraperitoneal dose of 0.2 ml sterile saline or rabbit IgG 00 mg/ml in saline ; Sigma 
In vivo regulation of serum Clq levels (69 ) 
Chemical Coよ Severalmice of each sex were sacrificed and their blood was obtained by 
cardiac puncture after anesthesia at 2，7 and 14 days after the adminstration of CY or saline， 
and at 1，3，5，7 and 10 days after the treatment with anti-TG or rabbit IgG. A part of the blood 
of each mouse was collected in 0.4 ml of isotonic 0.1 M EDT A (pH 7.4) (EDT A -blood)， and 
exact blood volume collected was calculated by measuring the weight. The remaining blood 
without adding EDT A was allowed to clot at 3TC for 60 min and then left at room temperature 
for 60 min. Serum was separated at 40C by centrifugation at 2000 g for 15 min 
Immunological quantitation of Clq， C3 and IgG 
This was carried out using a modification of the single radial immunodiffusion described by 
Mancini et a[23). Rabbit monospecific antiserum to mouse C1q was prepared acじordingto the 
method previously described24). Goat antisera to mouse C3 and rabbit antisera to mouse IgG 
were purchased from CAPPEL Organon Teknika Corp. (West Chester， P A， USA) and from 
Miles Laboratories， Inc. (Elkhard， IN， USA) respectively. These antisera were used after 
appropriate dilutions. 
Measurement of blood leukocyte， T and B lymphocytes 
Total counts of circulating leukocytes were made in a haemocytometer chamber by using the 
EDT A -blood obtained as described above after mixing it 1: 9 with a Turk solution. The 
lymphocyte rich fraction was obtained by overlaying each EDTA-blood onto a lymphohyte 
separation solution (M -SMF with the specific gravity 1. 090 ; J apan Immunoresearch Labora-
tories Co. Ltd.， Takasaki， Japan)， and after removal of erythrocytes by centrifugation at 1200 
g for 20 min. 
T lymphocytes in the lymphocyte rich fraction were measured by essentially the same 
Trypan blue dye-exclusion cytotoxic testing as described by Raff and Owen2円butscaled down 
by using poly-L-lysine coated Terasaki tissue culture plates (Becton Dickinson and Company， 
Lincoln Park， NJ， USA). The antiserum reagent used was an AKR mouse monoclonal antibody 
to CBA Thy-1.2 thymocytes (Thy-1.2 F7D5 monoclonal IgG cytotoxic antibody; SeroTec， 
Kidlington， Oxford， England) after heat inactivation at 560C for 30 min. Fresh guinea pig 
serum， absorbed with BALB/C mouse erythrocytes， was used as a source of complement. T 
lymphocyte counts were expressed as percentage'of dead cells stained with Trypan blue to the 
sum of dead and live lymphocyte populations. For B lymphocyte counts， cellsin the 
lymphocytes rich fraction were washed 3 times with cold RPMI 1640 (Flow Laboratories， 
North Ryde， N. S. W.， Australia) and incubated in the dark for 30 min at 40C with a 1: 20 
dilution of the fluorescein isothiocyanatelabelled F(ab')2 fragment of goat anti-mouse IgM 
(CAPPEL Organon Teknika Corpふ Thecells were washed 3 times with cold phosphate 
buffered saline， fluorescent B lymphocytes were counted under a fluorescence microscope 
Percentages of B lymphocytes to cells in the lymphocyte rich fraction were also calculated. 
Statintical analysis of data 
Experimentally measured values in each group were expressed as the mean:tone standard 
deviation (S. DふThestatistical significance of the difference of the means of C1q， C3， and IgG 
(70 ) T. Sasaki， etal. 
levels in CY -， anti-TG-and rabbit IgG-treated mice from those in saline-treated mice was 
calculated by Behrez-Fisher z test because of the unequality of each variance. The degree of 
the significance was tested with a t table and probability levels(P) were calculated. These 
statistical analysis methods have been described by Snedecor and Cochran26). 
RESULTS 
Effect of CY on serum levels of Clq， C3 and IgG， and on blood T and B lymphocyte counts 
Total 88 BALB/c mice (46 male and 42 female) were used. Each of these mice was treated 
with a single intraperitoneal dose of CY (300μg/g or 400μg/ g body weight) or saline. On 2，7 
or 14 days after the treatment， several mice were sacrificed and their serum C1q， C3 and IgG， 
and peripheral blood leukocytes， T and B lymphocytes were measured. 
The mean values and the S. D. of C1q， C3 and IgG levels in each group according to sex and 
days after treatment were calculated and are presented in Fig. 1. In the CY -treated mice， both 
C1q and IgG levels were highly suppressed : the mean levels of C1q and of IgG corresponded to 
44-68% and to 38-54% of those of their respective saline-treated mice， respectively. Such 
suppression was more conspicuous in male than in female mice， and also more conspicuous in 
the mice treated with the higher dose of CY. The suppression was statistically significant in 
male mice from 2 through 14 days 包<0.001)， and significant in female only on 14 days (p < 
0.01) after the treatment. In contrast， C3 levels in the CY -treated mice of both sexes were 
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Fig. 1. Serum C1q C3 and IgG lev巴Isin BALB! c mice on 2， 7 and 14 days aft巴rcyc1ophosphamide CCY) 
treatm巴nt.Values ar巴 r巴presentedas the mean土1Standard d巴vdation. 口:saline-tr巴atedmale 
controls ;・:sa1ine-treated female controls; 0: 300μg! g CY -treat巴dmale mice ;・:300μg! 
g CY -treated female mic巴;ム:400μg! g CY -treated mal巴mice;.・ 400μg!gCY-treated f巴mal巴
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significantly increased to 142%-169% of the levels of their respective saline-treated control on 
2 days (p < 0.01) and on 7 days (1う<0.05) after treatment. 
The mean values and the S. D. of blood leukocyte counts， T and B lymphocyte counts were 
calculated and presented in Table 1. In the CY -treated mice in both sexes， total blood 
leukocyte counts were highly suppressed to 8%-63% of those of their respective saline-treated 
controls from 2 through 7 days after the treatment. The suppression was more conspicuous in 
male (P < 0.001) than in female (P < 0.01) mice and more conspicuous in the mice with 400μg/ 
g CY (P < 0.001) than in those with 300μg/g CY (P<O.01). In the CY-treated mice， percent-
ages of B lymphocytes to cells in the lymphocyte rich fractions were also markedly reduced to 
12%-76% of those of respective saline-treated controls through the entire period tested. Such 
reduction was also more conspiuous in male than in female mice and in the 400μg/g CY-
treated mice than in the 300μg/g CY -treated mice. Percentage of T lymphocytes slightly 
increased in the CY -treated mice， but such increase was not statistically significant， and 
numbers of T cells were actually reduced. 
In viωr巴gulationof serum Clq levels 
Effect of anti-TG on serum levels of Clq， C3 and IgG， and on blood T and B lymphocyte 
counts 
Total124 BALB/c mice (63 male and 61 female) were used. Each of these mice was treated 
with a single intraperitonealdose of rabbit anti-TG， rabbit IgG or saline. On 1， 3， 5， 7， and 10 
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Fig. 2. Serum Clq， C3 and IgG lev巴Isin BALB!c mice on 1， 3， 5， 7 and 10 days aft巴ranti-thymocyte-globulin 
Canti-TG)一treatment.Values are repres巴ntedas the m巴an:t 1 standard deviation 口:salin巴ーtreated
male mice; ・:saline-tr巴atedf巴mal巴 mic巴 o: anti-TG-treated male mice; ・anti-TG 
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peripheral blood leukocytes， T and B lymphocytes were measured. The mean values and the 
s. D. of C1q， C3 and IgG levels in each group accroding to sex and days after the treatment 
were calculated and are presented in Fig. 2. In the anti-TG-treated male mice， C1q levels were 
suppressed to 55-67% of that of the saline-treated male mice 包 <0.001) from 5 through 10 
days after the treatment. In the anti-TG-treated female mice， C1q levels were suppressed to 
41-70% of that of the saline-treated female mice on 1 day 住<0.01)and on 3 days (ρ< 0.05) 
and 5-10 days (ρ< 0.001) after the treatment. In these female mice， IgG levels were also 
slightly suppressed to 77%-86% of those of the saline-treated female mice. C3 levels of the anti 
-TG-treated female mice and IgG levels of the anti-TG-treated male mice highly increased on 
1 day and on 7 day after treatment respectively. In the rabbit-IgG-treated mice， no significant 
deviatitons were observed in either C1q， C3 or in IgG levels from those of their respective saline 
treated controls. 
The mean values and the S. D. of blood leukocyte counts， T and B lymphocyte counts were 
calculated and presented in Table 2. In the anti-TG-treated mice of both sexes， totalleuko-
cyte counts were highly suppressed to 8%-73% of those of their respective saline-treated mice 
from 1 through 7 days after the treatment. The suppression was highly significant on 1-3 days 
(ρ< 0.001) and moderately significant on 5-7 days (p < 0.01) after the treatment. In these 
mice， percentage of blood T lymphocytes to cells in lymphocyte rich fractions were also 
markedly reduced to 2.8%-36% of those of respective saline-treated controls through the entire 
period tested. Percentages of B lymphocytes in the anti-TG-treated mice were reduced. In 
contrast， similar administration of rabbit IgG had no significant effects either on total leuko-
cyte， T or on B lymphocyte counts through the entire period tested 
(72 ) 
Tabl巴1. Effect of cyclophosphamid巴 CCY)on total leukocyt巴 countsand 
onp巴rcentagesof T and B lymphocyt巴ダ
Cels 



































































Male 0.64土0.21t 72.6土17.5 8.5土2.1
Fernale 6 0.73士0.41t 75.3士10目9 目4士1.8
Male 6 3.45土1.50t 67.2土 8.5 3.4土1.1
Fernale 7 4.42士1.6t 68.3士 7.4 5.5士1.2
Male 6 6目95士1.72 58.1士 8.3 6.4士2.4
Fernale 6 7. 40土3.08 63.2土 9.2 10.1土2.6
ホEachBALB/c rnouse was given a single intraperitoneal injection of CY (300μg/g or 400μg/ 
g body weight). Mice were sacrificed and their white blood cels， T and B cels were counted 
on days indicated. Valu巴sare r巴presentedas the rnean土 onestandard deviation. Significantly 






In vivo r巴gulationof serum Clq levels (73 ) 
Tabl巴 2.Eff巴ctof anti-thymocyte-globulin Canti-TG) on total leukocyte counts and 
on perc巴ntagesof T and B lymphocytes* 
Days Number C巴ls
Treatment after Sex of mice Total leukocytes T cel (%) B cel (%) 
treatment used (x10' /mm') 
Saline Male 12 7.82士2.96 56.7土7.7 26.5土9.2
Female 10 7.95土1.51 58.6土9目8 21. 5土6.8
Anti-TG l Male 4 0.97土0.31t 4.62士1目1 13目。士1.5
Female 0.6士0.21t 1目63士0.1 16.3土4.8
3 Male 2.4土1.12t 6.63土2.8 30.4土4.8
Female 5 2.12士0.45t 6.67士1.1 29.3士1.4
5 Male 8.5土0.28 9.31土0.7 27.2土1.6
Female 5 5.19土1.63t 8.82士1.7 21. 4士3.5
7 Male 4 5目69士1.91 9目75土4.9 26.6土4.9
Female 6 5.28土1.80t 10.2土4.0 19.7士7.2
10 Male 4 8.02士1.27 18.3 :t4.6 29.3土5.8
Female 7.06土1.47 21.2土8.7 27.1士5.6
Rabbit IgG 3 Male 7.65土2.47 58.3土5.8 23.3士5.8
Female 7.42士1.98 63.1士7.4 17.4土3.3
7 Male 7.23土2.51 62.5土7.0 28.4:t7.1 
Female 6 7.82士2.70 54.0士6.2 2.4士4目3
10 Male 5 6.98土1.65 60.3土9.8 27.8土4.8
Female 8.03士3目24 53.8土5.5 28.9土6.3
*Each BALB/c mouse was given a sigle intraperitoneal injection of anti-TG or mabbit IgG 
Micewere sacrificed and their white blood cels， T and B cels were measured on days indicated 
Values ar巴representedas the mean土onestandard deviation. Significantly deviated with P < 
O.Ol(t) and p<o.ol(tn from thos巴ofrespective saline-treat巴dcontrols. 
DISCUSSION 
In this study， we have artificially regulated B and T cell functions in mice by in vivo 
administration of CY and/or anti-TG， and immunochemically measured their serum C1q and 
C3 levels in parallel with those of serum IgG. 
Dosages of CY used in this study were 300μg/g and 400μg/ g body weight and had strong 
leukopenic effects in BALB/c mice. Its suppressive effect on numbers of peripheral blood 
lymphocytes was more severe and long-lasting on the B cell compartment than on the T cell 
compartment， and the effect on B cells lasted at least up to 14 days after the administration 
CTable 1). These results actually agree well with the report by Stockman et al27}. All the mice 
given the 400μg/g dose in this study survived up to 14 days after treatment， which showed 
BALB/c mice were more resistant to the toxic effects of CY than CC57BL!6 xA) Fl mice27}. A 
slight reduction of B cell populations besides a more severe reduction of T cell populations was 
observed in this study by using a commercially available anti-TG reagent CTable 2) ; the 
reason for which could not be identified， but it is most likely due to the low specificity of this 
antibody preparation as anti-mouse-Thy-1 reagents 
Treatment of the mice with CY diminished serum C1q levels as well as IgG levels CFig. 1). 
Treatment with anti-TG reagent also diminished serum C1q levels CFig. 2). These results and 
the fact that B cell population was also impaired in anti-TG treated mice as in CY -treated mice 
suggest that B cell impairment may cause reduced maturation of serum C1q levels as well as 
(74 ) T. Sasaki， etal. 
that of serum IgG levels. These results may correspond to those obtained in patients with 
Bruton type hypogammaglobu1inemia5)ベinwhich only their immunoglobu1in producing system 
was impaired but their cell-mediated immunity was not apparently defective and both of their 
seum Clq and IgG levels were markedly diminished. These results also agree well with our 
previous report28) that embryonic surgical bursectomy of chicken diminished markedly their 
serum Clq as well as IgG levels. 
Marked decreases of Clq were also reported in patients with Swiss type lymphopenic 
aggammaglobu1inemia， in which both types of cell-mediated and huroral immunity were 
impaired， by Gewurz et aF9)， and in athymic BALB/c-nu Cnude) mice by us7). These reports 
have yielded a possibi1ity， whi1e itremains to bo further clarified， that decrease of serum Clq 
levels observed in the present study might be related to impairment of T cel populations by CY 
and/or asti-TG. In addition， because the lack of any effects of rabbit IgG either on blood 
lymphocyte populations CTable 2)， serum Clq or C3 levels CFig. 2)， these regulatory activites 
of anti-TG are supposed to be immunologically specific. 
Data presented in this report also showed that serum C3 levels were markedly increased in 
the mice treated with CY shortly after administration CFig. 1)， which might be caused by a 
possible enhancing effect of CY simi1ar to that described in delayed-type hypersensitivity with 
a smaller dose of CY by Askenase et aPO). Mechanisms of such a conspicuous increase of IgG 
levels at 7 days after the anti-TG-treatment in male mice CFig. 2) could not be clarified; no 
antibodies to rabbit IgG were detected by using a passivenaemaglutination test with rabbit IgG 
coated sheep erythrocytes Cdata not shown). Furthermore， data in this study showed that 
male mice were more susceptible to the suppressive effects of CY on serum Clq and IgG levels 
than female mice CFig. 1). The exact mechanisms of this finding should be elucidated. 
In conclusion， the present study indicates that there are some regulatory 1inks between serum 
Clq levels and functions of B lymphocytes Cand also possibly those of T lymphocytes) in mice. 
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